| Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells CJ Turtle, LA Hanafi, C Berger, M Hudecek, B Pender, E Robinson, ... Science translational medicine 8 (355), 355ra116-355ra116, 2016 | 1055 | 2016 |
| Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy KA Hay, J Gauthier, AV Hirayama, JM Voutsinas, Q Wu, D Li, TA Gooley, ... Blood, The Journal of the American Society of Hematology 133 (15), 1652-1663, 2019 | 346 | 2019 |
| Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure J Gauthier, AV Hirayama, J Purushe, KA Hay, J Lymp, DH Li, CCS Yeung, ... Blood, The Journal of the American Society of Hematology 135 (19), 1650-1660, 2020 | 293 | 2020 |
| The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu, T Gooley, D Li, ... Blood, The Journal of the American Society of Hematology 133 (17), 1876-1887, 2019 | 293 | 2019 |
| Androgen receptor activity in T cells limits checkpoint blockade efficacy X Guan, F Polesso, C Wang, A Sehrawat, RM Hawkins, SE Murray, ... Nature 606 (7915), 791-796, 2022 | 210 | 2022 |
| Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy A Sheih, V Voillet, LA Hanafi, HA DeBerg, M Yajima, R Hawkins, V Gersuk, ... Nature communications 11 (1), 219, 2020 | 198 | 2020 |
| High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu, BS Pender, ... Blood, The Journal of the American Society of Hematology 134 (7), 636-640, 2019 | 173 | 2019 |
| Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies J Gauthier, ED Bezerra, AV Hirayama, S Fiorenza, A Sheih, CK Chou, ... Blood, The Journal of the American Society of Hematology 137 (3), 323-335, 2021 | 124 | 2021 |
| Comparison of efficacy and toxicity of CD19-specific chimeric antigen receptor T-cells alone or in combination with ibrutinib for relapsed and/or refractory CLL J Gauthier, AV Hirayama, KA Hay, D Li, J Lymp, A Sheih, J Purushe, ... Blood 132 (Supplement 1), 299-299, 2018 | 62 | 2018 |
| Efficacy and toxicity of JCAR014 in combination with durvalumab for the treatment of patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma AV Hirayama, J Gauthier, KA Hay, A Sheih, S Cherian, X Chen, ... Blood 132 (Supplement 1), 1680-1680, 2018 | 38 | 2018 |
| Efficacy and toxicity of CD19-specific chimeric antigen receptor T cells alone or in combination with ibrutinib for relapsed and/or refractory CLL J Gauthier, AV Hirayama, KA Hay, D Li, J Lymp, A Sheih, J Purushe, ... Biology of Blood and Marrow Transplantation 25 (3), S9-S10, 2019 | 13 | 2019 |
| Factors associated with duration of response after CD19-specific CAR-T cell therapy for refractory/relapsed B-cell non-Hodgkin lymphoma. J Gauthier, AV Hirayama, KA Hay, D Li, A Sheih, V Wu, JM Voutsinas, ... Journal of Clinical Oncology 36 (15_suppl), 7567-7567, 2018 | 11 | 2018 |
| A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy AV Hirayama, CK Chou, T Miyazaki, RN Steinmetz, HA Di, SP Fraessle, ... Blood Advances 7 (11), 2479-2493, 2023 | 9 | 2023 |
| Factors associated with response, CAR-T cell in vivo expansion, and progression-free survival after repeat infusions of CD19 CAR-T cells ED Bezerra, J Gauthier, AV Hirayama, BS Pender, RM Hawkins, A Vakil, ... Blood 134, 201, 2019 | 9 | 2019 |
| Combination of NKTR-255, a polymer conjugated human IL-15, with CD19 CAR T cell immunotherapy in a preclinical lymphoma model C Chou, S Fraessle, R Steinmetz, RM Hawkins, TD Phi, D Busch, ... Blood 134, 2866, 2019 | 6 | 2019 |
| Immunotherapy with T-cells engineered with a chimeric antigen receptor bearing a human CD19-binding single chain variable fragment for relapsed or refractory acute … J Gauthier, AV Hirayama, KA Hay, A Sheih, BS Pender, RM Hawkins, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 6 | 2018 |
| Factors impacting disease-free survival in adult B cell B-ALL patients achieving MRD-negative CR after CD19 CAR-T cells. KA Hay, J Gauthier, AV Hirayama, D Li, A Sheih, V Wu, JM Voutsinas, ... Journal of Clinical Oncology 36 (15_suppl), 7005-7005, 2018 | 5 | 2018 |
| Factors impacting progression-free survival after CD19-specific CAR-T cell therapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, QV Wu, T Gooley, D Li, ... Blood 132, 1681, 2018 | 2 | 2018 |
| Durable responses after CD19‐targeted CAR‐T cell immunotherapy with concurrent ibrutinib for CLL after prior ibrutinib failure J Gauthier, AV Hirayama, KA Hay, J Lymp, D Li, A Sheih, J Purushe, ... Hematological Oncology 37, 168-170, 2019 | 1 | 2019 |
| PS1208 EFFECTS OF NKTR-255, A POLYMER CONJUGATED HUMAN IL-15, ON EFFICACY OF CD19 CAR T CELL IMMUNOTHERAPY IN A PRECLINICAL LYMPHOMA MODEL C Chou, SP Fräßle, RM Hawkins, RN Steinmetz, TD Phi, DH Busch, ... HemaSphere 3 (S1), 550, 2019 | 1 | 2019 |
